Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Πέμπτη 24 Μαΐου 2018
The Lymph Node and the Metastasis
Women with breast cancer who have breast cancer cells in one or more lymph nodes have poorer outcomes than women without node involvement. Although many oncologists believe that this phenomenon is explained by the dissemination of metastatic cells through the lymphatic system, findings reported in…
https://ift.tt/2x7daFb
p53 and Me
I started medical school in 2010, the year of my genetic crisis. Before moving to Boston to begin classes, I went to the overly air-conditioned basement of a plain building on a swanky block of Manhattan. The physician who ran the center took time to explain, in kind and measured terms, the…
https://ift.tt/2x7d945
Τετάρτη 23 Μαΐου 2018
Avelumab: A Review in Metastatic Merkel Cell Carcinoma
Abstract
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that is directed against programmed cell death ligand 1 (PD-L1). Avelumab functions as an immune checkpoint inhibitor and has recently been approved in the USA, the EU and Japan for the treatment of metastatic Merkel cell carcinoma (MCC). It is thus the first therapeutic agent specifically approved for use in this indication, and is approved for use independent of line of treatment. Approval for avelumab in metastatic MCC was based on the two-part, single-arm, phase II trial, JAVELIN Merkel 200. In Part A of the study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab. The responses were observed early and appeared to be durable, with an estimated 74% of responses having a duration ≥ 12 months. Furthermore, interim results from a separate cohort of patients (Part B) indicate an objective response rate for avelumab of > 60% in patients who were chemotherapy-naïve in the metastatic disease setting. Avelumab is associated with a risk of immune-related adverse events but, overall, has an acceptable and manageable safety and tolerability profile. In conclusion, currently available data suggest that avelumab presents a clinically beneficial new treatment option for metastatic MCC, a rare but aggressive cancer associated with a poor prognosis. 
https://ift.tt/2kiRVam
Case 16-2018: A 45-Year-Old Man with Fever, Thrombocytopenia, and Elevated Aminotransferase Levels
Presentation of Case. Dr. Alyssa Sclafani (Medicine): A 45-year-old man presented to the emergency department of this hospital during the summer with fever, thrombocytopenia, and elevated aminotransferase levels. Three weeks before presentation, fever occurred (with temperatures as high as 40.0°C),…
https://ift.tt/2GJonvp
Odd‐skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and β‐catenin
Cancer Science, EarlyView.
https://ift.tt/2IILaZM
Εγγραφή σε:
Αναρτήσεις (Atom)